GLUT1 deficiency syndrome: an update.

Area of Science:

• Genetics
• Neurology
• Metabolic Disorders

Background:

• Glucose transporter type 1 deficiency syndrome (G1D) arises from SLC2A1 gene mutations, impairing brain glucose supply and causing cerebral energy deficits.
• The condition presents with a diverse range of symptoms, including intellectual disability, microcephaly, motor impairments, and episodic events like seizures.
• Mild G1D cases may exhibit only episodic symptoms, necessitating consideration in patients with paroxysmal exercise-induced dyskinesia or early-onset epilepsy.

Purpose of the Study:

• To highlight the diagnostic challenges and clinical significance of Glucose transporter type 1 deficiency syndrome.
• To emphasize the importance of recognizing G1D for timely and effective treatment.

Main Methods:

• Review of clinical phenotypes associated with SLC2A1 mutations.
• Analysis of diagnostic biochemical and molecular markers.
• Discussion of current therapeutic strategies, primarily the ketogenic diet.

Main Results:

• G1D is characterized by a wide spectrum of neurological and episodic symptoms.
• Low cerebrospinal fluid glucose levels are a key indicator, though not always present.
• Molecular genetic testing of the SLC2A1 gene provides definitive diagnosis.

Conclusions:

• Glucose transporter type 1 deficiency syndrome is likely underdiagnosed due to its complex presentation.
• Prompt identification is critical for initiating treatment and improving patient outcomes.
• The ketogenic diet is the primary treatment, requiring multidisciplinary management.